Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Bina Cipta Husada: Jurnal Kesehatan dan Science
Putri, Devi Andiani
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Dentistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Evaluasi Rasionalitas Peresepan dan Penggunaan Obat Antiepilepsi pada Pasien Epilepsi Poli Saraf Rosvita, Fara; Rosyadi, Anwar; Wibowo, Edwar Randi; Putri, Devi Andiani
Jurnal Bina Cipta Husada Vol 22 No 1 (2026): Jurnal Bina Cipta Husada
Publisher : STIKes Bina Cipta Husada

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Epilepsi merupakan gangguan neurologis kedua tertua setelah stroke yang memerlukan terapi jangka panjang dengan Obat Antiepilepsi (OAE). Penggunaan OAE harus rasional untuk mencegah efek samping dan mencapai tujuan terapi yang optimal. Tujuan penelitian ini untuk mengevaluasi rasionalitas peresepan dan penggunaan OAE pada pasien epilepsi poli saraf di RSU Aghisna Medika Sidareja periode Juli-Oktober 2024. Metode penelitian ini bersifat deskriptif dengan pendekatan retrospektif. Data yang diambil dari rekam medik pasien epilepsi poli saraf. Evaluasi meliputi skrining administrasi, farmasetik, dan klinis, pola penggunaan OAE, serta rasionalitas berdasarkan parameter 4T (tepat indikasi, tepat pasien, tepat obat, tepat dosis). Hasil penelitian menunjukkan bahwa dari 189 pasien, mayoritas berjenis kelamin perempuan (57,7%) dengan kelompok usia terbanyak adalah dewasa (20-44 tahun) sebesar (67,2%). Skrining resep menunjukkan kelengkapan kategori administrasi pada nama pasien (100%) dan kategori farmasetik pada nama obat (100%). Evaluasi rasionalitas menunjukkan ketepatan indikasi, pasien, dan obat sebesar 100%, sedangkan ketepatan dosis sebesar (92,1%). Monoterapi paling banyak digunakan adalah phenytoin (56,6%), sedangkan politerapi terbanyak adalah kombinasi phenytoin dan divalproex sodium (12,2%). Kesimpulan yang dapat diambil yaitu peresepan dan penggunaan OAE poli saraf di RSU Aghisna Medika Sidareja umumnya sudah rasional, namun masih terdapat ketidaktepatan dosis pada sebagian resep.
Cost-Utility Analysis Addition of Bevacizumab to Standard Chemotherapy in KRAS-mutation Colorectal Cancer Putri, Devi Andiani; Setiawan, Didik; Yamsun, Muhammad
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Pharmacy, Vol. 22 No. 01 Juli 2025
Publisher : Pharmacy Faculty, Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30595/pharmacy.v22i1.24298

Abstract

There is a high incidence of colorectal cancer in Indonesia. Colorectal cancer was ranked fourth with an incidence of 8.6% and a colon cancer mortality rate of 4% while rectal cancer was 3.6% in Indonesia. The addition of Bevacizumab to Standard chemotherapy (FOLFOX/FOLFIRI/XELOX) in KRAS-mutation colorectal cancer patients has better clinical outcomes; however, it has a very high cost in terms of colorectal cancer treatment. The objective of this study was to determine the utility and economic impact of adding Bevacizumab as an adjunct therapy for KRAS-mutation colorectal cancer patients. A Markov model was developed to estimate the Cost-utility analysis (CUA) using a societal perspective. Humanistic outcomes are expressed in the form of QALY (Quality-adjusted life years) using an EQ-5D-5L instrument with an Indonesian value set. Medical expenses data were collected from both RSUP Dr. Sardjito and patients. Utility data were obtained from interviews with 30 patients undergoing chemotherapy at the hospital. This study compared the cost and utility of patients receiving Bevacizumab supplementation or patients receiving standard chemotherapy alone. The societal perspective resulted in a cost-effectiveness ratio (ICER) of US$3.098 per QALY. The addition of Bevacizumab to standard chemotherapy in KRAS-mutation colorectal cancer patients is considerably cost-effective from a societal perspective.
Co-Authors Didik Setiawan Rosvita, Fara Rosyadi, Anwar Wibowo, Edwar Randi Yamsun, Muhammad